Hyderabad, India and Princeton, NJ, USA. November 28, 2018— Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Chlorthalidone Tablets USP, 25 mg and 50 mg, a therapeutic equivalent generic version of Hygroton (chlorthalidone) Tablets, approved by the U.S. Food and Drug Administration (USFDA).
The Hygroton brand and generic had U.S. sales of approximately $122 million MAT for the most recent twelve months ending in September 2018 according to IMS Health*.
Dr. Reddy’s Chlorthalidone Tablets, USP are available in 25 mg tablets in the bottle-count sizes of 100 and 1000, and 50 mg tablets in the bottle-count size of 100.
*IMS National Sales Perspective: Retail and Non-Retail MAT September 2018
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
Notify me of follow-up comments by email.
Notify me of new posts by email.
2014 The Global Indian New Network (TGINN)